June 20, 2017 Issue of JAMA

June 20, 2017, Vol 317, No. 23, Pages 2347-2460

This Week in JAMA

Highlights

Abstract Full Text

free access has audio

JAMA. 2017;317(23):2347-2349. doi:10.1001/jama.2016.13174

Podcast: Cancer risk in BRCA carriers, effects of an internet-based weight loss program for low-income women, screening for obesity in children, and more

Original Investigation

Effect of an Internet-Based Program on Weight Loss for Low-Income Postpartum Women: A Randomized Clinical Trial

Suzanne Phelan, PhD; Todd Hagobian, PhD; Anna Brannen, MS; et al.

Abstract Full Text

free access

JAMA. 2017;317(23):2381-2391. doi:10.1001/jama.2017.7119

This cluster randomized clinical trial assessed the effects of adding an internet-based weight loss intervention program to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC program) on weight loss over 12 months among low-income, postpartum women.

Editorial
Losing Weight During the Postpartum Period
Adam Gilden Tsai, MD, MSCE; Wanda K. Nicholson, MD, MPH, MBA

JAMA

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Alan P. Venook, MD; Donna Niedzwiecki, PhD; Heinz-Josef Lenz, MD; et al.

Abstract Full Text

free access

JAMA. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105

This randomized clinical trial compares the effect of adding bevacizumab vs cetuximab to standard chemotherapy regimens on overall survival among patients with advanced or metastatic KRAS wild-type colorectal cancer.

Editorial
Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same
Christopher H. Lieu, MD; Wells A. Messersmith, MD

JAMA

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Karoline B. Kuchenbaecker, PhD; John L. Hopper, PhD; Daniel R. Barnes, PhD; et al.

Abstract Full Text

free access

JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112

This cohort study estimates age-specific risks of breast, ovarian, and contralateral breast cancer among carriers of BRCA1 and BRCA2 mutations and evaluates risk modification by family cancer history and location of the mutation within the BRCA gene.

Research Letter

Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014

Mary R. Rooney, MPH; Lisa Harnack, DrPH, RD; Erin D. Michos, MD, MHS; et al.

Abstract Full Text

free access

JAMA. 2017;317(23):2448-2450. doi:10.1001/jama.2017.4392

This study uses NHANES data to assess trends in supplemental vitamin D intake of 1000 IU or more and 4000 IU or more daily between 1999 and 2014.

US Preventive Services Task Force

Recommendation Statement

Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force

Abstract Full Text

free access has audio

JAMA. 2017;317(23):2417-2426. doi:10.1001/jama.2017.6803

This Recommendation Statement from the US Preventive Services Task Force recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer or refer them to comprehensive, intensive behavioral interventions to promote improvements in weight (B recommendation).

Podcast: USPSTF Recommendation: Screening for Obesity in Children and Adolescents

Editorial
Putting the US Preventive Services Task Force Recommendation for Childhood Obesity Screening in Context
Rachel L. J. Thornton, MD, PhD; Raquel G. Hernandez, MD, MPH; Tina L. Cheng, MD, MPH

JAMA
The Promise and Opportunities for Screening and Treating Childhood Obesity: USPSTF Recommendation Statement
Teresa Quattrin, MD; Denise E. Wilfley, PhD

JAMA Pediatr
Practical Considerations for the US Preventive Services Task Force Recommendations on Obesity in Children and Adolescents
Jason P. Block, MD, MPH; Emily Oken, MD, MPH

JAMA Intern Med

Evidence Report

Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force

Elizabeth A. O鈥機onnor, PhD; Corinne V. Evans, MPP; Brittany U. Burda, DHSc, MPH; et al.

Abstract Full Text

free access

JAMA. 2017;317(23):2427-2444. doi:10.1001/jama.2017.0332

This Evidence Report and systematic review to support the 2017 US Preventive Services Task Force Recommendation Statement on screening for obesity summarizes current evidence on the benefits and harms of screening and treatment for obesity and overweight in children and adolescents.

Editorial
Putting the US Preventive Services Task Force Recommendation for Childhood Obesity Screening in Context
Rachel L. J. Thornton, MD, PhD; Raquel G. Hernandez, MD, MPH; Tina L. Cheng, MD, MPH

JAMA
The Promise and Opportunities for Screening and Treating Childhood Obesity: USPSTF Recommendation Statement
Teresa Quattrin, MD; Denise E. Wilfley, PhD

JAMA Pediatr
Practical Considerations for the US Preventive Services Task Force Recommendations on Obesity in Children and Adolescents
Jason P. Block, MD, MPH; Emily Oken, MD, MPH

JAMA Intern Med

Viewpoint

Management of Chronic Pain in the Aftermath of the Opioid Backlash

Kurt Kroenke, MD; Andrea Cheville, MD

Abstract Full Text

JAMA. 2017;317(23):2365-2366. doi:10.1001/jama.2017.4884

This Viewpoint argues that abandoning opioids on principal may be premature and could harm patients successfully treating their chronic pain with opioids.

Primary Care of Patients With Chronic Pain

Jill Schneiderhan, MD; Daniel Clauw, MD; Thomas L. Schwenk, MD

Abstract Full Text

JAMA. 2017;317(23):2367-2368. doi:10.1001/jama.2017.5787

This Viewpoint advocates for reducing opioid misuse among primary care patients with chronic pain through a comprehensive approach emphasizing shared decision making, nonpharmacological treatments, nonopioid therapy, and a focus on functional improvement rather than pain elimination.

Text Messaging and Protected Health Information: What Is Permitted?

Brian C. Drolet, MD

Abstract Full Text

JAMA. 2017;317(23):2369-2370. doi:10.1001/jama.2017.5646

This Viewpoint discusses the best use of texting clinical information, noting that neither Health Insurance Portability and Accountability Act nor the Health Information Technology for Economic and Clinical Health Act offer specific guidelines.

The Next Generation of Episode-Based Payments

Amol S. Navathe, MD, PhD; Zirui Song, MD, PhD; Ezekiel J. Emanuel, MD, PhD

Abstract Full Text

JAMA. 2017;317(23):2371-2372. doi:10.1001/jama.2017.5902

This Viewpoint discusses bundled payment models and suggests ways in which the next generation of episode-based payments can better align with population health.

A Piece of My Mind

Speak Up

Douglas G. Merrill, MD, MBA

Abstract Full Text

JAMA. 2017;317(23):2373-2374. doi:10.1001/jama.2017.2022

Editorial

Losing Weight During the Postpartum Period

Adam Gilden Tsai, MD, MSCE; Wanda K. Nicholson, MD, MPH, MBA

Abstract Full Text

JAMA. 2017;317(23):2375-2376. doi:10.1001/jama.2017.7036

Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same

Christopher H. Lieu, MD; Wells A. Messersmith, MD

Abstract Full Text

JAMA. 2017;317(23):2376-2378. doi:10.1001/jama.2017.6673

Putting the US Preventive Services Task Force Recommendation for Childhood Obesity Screening in Context

Rachel L. J. Thornton, MD, PhD; Raquel G. Hernandez, MD, MPH; Tina L. Cheng, MD, MPH

Abstract Full Text

JAMA. 2017;317(23):2378-2380. doi:10.1001/jama.2017.3434

JAMA Performance Improvement

Phenytoin Toxicity

Arjun Gupta, MD; Christina Yek, MD; Robert S. Hendler, MD

Abstract Full Text

has audio

JAMA. 2017;317(23):2445-2446. doi:10.1001/jama.2017.6881

This JAMA Performance Improvement article uses the case of a patient with iatrogenic phenytoin toxicity due to an excess prescribed dosage to discuss proper handling and reporting of significant adverse drug events.